Evotec reaches first milestone with Cardioxyl CXL-1020

Published: 2-Oct-2009
Research & Development

Cardioxyl Pharmaceuticals has made its first milestone payment to Evotec


Evotec has reached an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, which has moved into clinical testing. Cardioxyl Pharmaceuticals has made its first milestone payment to Evotec.

Evotec has been providing medicinal chemistry support to Cardioxyl for more than three years. During this time CXL-1020 has been taken from lead optimisation to pre-clinical development, and has now progressed to Phase I/IIa testing in heart failure patients. Using its expertise in lead optimisation and computer-aided drug design (CADD), Evotec has optimised a range of molecules with the aim of identifying clinical compounds.

See more

You may also like

Research & Development

SynaptixBio and Evotec collaborate to develop novel antisense oligonucelotides for H-ABC

Read more
The companies will look to discover novel antisense oligonucleotides targeting mutant TUBB4A for the treatment of H-ABC

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

SynaptixBio and Evotec collaborate to develop novel antisense oligonucelotides for H-ABC

The companies will look to discover novel antisense oligonucleotides targeting mutant TUBB4A for the treatment of H-ABC
Research & Development

Pharma giants join £9.5 million dementia drug discovery collaboration

Johnson & Johnson Innovation, Takeda and Evotec have joined The Dementia Consortium
Research & Development

Galapagos expands fibrosis portfolio

Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development

Evotec and ABIVAX collaborate to develop novel antiviral agents

Evotec and ABIVAX have announced a strategic collaboration to discover and develop novel treatments for multiple viral infectious diseases
Media

Evotec to acquire Aptuit, expanding leadership in external innovation

Evotec and Aptuit have entered into a definitive agreement, Evotec will acquire Aptuit for US$ 300 million
Research & Development

Eternygen GmbH closes €8.0 million series A financing led by Epidarex Capital

Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, has announced the completion of its €8.0 million Series A funding round
Research & Development

Evotec and ex scientia join forces to discover bispecific small molecule immuno-oncology therapeutics

Initial focus will be cancer-related adenosine targets which are increasingly recognised to play important roles in immuno-oncology
Subscribe now